Holen Sie sich die Stockscreener-App
3.04
6.67%
0.19
Handel nachbörslich:
3.00
-0.04
-1.32%
Schlusskurs vom Vortag:
$2.85
Offen:
$2.84
24-Stunden-Volumen:
74,547
Relative Volume:
0.68
Marktkapitalisierung:
$19.20M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-11.46M
KGV:
-0.2171
EPS:
-14
Netto-Cashflow:
$-24.56M
1W Leistung:
+7.42%
1M Leistung:
+14.29%
6M Leistung:
+16.48%
1J Leistung:
-77.52%
1-Tages-Spanne:
$2.83
$3.05
1-Wochen-Bereich:
$2.7235
$3.05
52-Wochen-Spanne:
$1.20
$17.75
Evaxion A S Adr Stock (EVAX) Company Profile
Vergleichen Sie EVAX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EVAX
Evaxion A S Adr
|
3.04 | 17.50M | 0 | -11.46M | -24.56M | -14.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Evaxion A S Adr Stock (EVAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-04-02 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2024-02-12 | Eingeleitet | H.C. Wainwright | Buy |
Evaxion A S Adr Aktie (EVAX) Neueste Nachrichten
Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025 - GlobeNewswire Inc.
Short Interest in Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Expands By 148.8% - Defense World
Evaxion Boosts Equity through Debt Conversion, Improves Financial Flexibility - AInvest
Healthcare Stocks to Watch: Evaxion Biotech, CVRx, and Rockwell Medical Receive Bullish Sentiments - AInvest
Biotech Contrarians: Seizing Value in Europe's ADRs Amid Sectoral Slump - AInvest
European ADRs Dip As Evaxion And Grifols Climb - Finimize
European ADRs Dip While Biotech And Energy See Gains - Finimize
EVAX: Grant For Polio Vaccine Announced - Research Tree
Evaxion Biotech’s Earnings Call Highlights Progress and Challenges - MSN
Evaxion Biotech Reports Q1 2025 Progress and Financials - TipRanks
European ADRs Rise On S&P Europe Select Index - Finimize
Evaxion reports progress in cancer vaccine trial, extends cash runway - Investing.com
European Equities See Growth In US Trade - Finimize
80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - GlobeNewswire Inc.
Evaxion’s EVX-01 vaccine shows promising immune response in trial - Investing.com
European Equities Traded in the US as American Depositary Receipts Sharply Higher in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Drop in Monday Trading - TradingView
European Stocks Slip In US Trading With Mixed Performances - Finimize
Evaxion Biotech’s Optimistic Earnings Call Highlights - TipRanks
Evaxion Biotech Reports 2024 Financial Results and Strategic Progress - TipRanks
European Equities Traded in the US as American Depositary Receipts Tread Water in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading - TradingView
Evaxion Biotech stock plunges to 52-week low of $1.7 amid steep annual decline - Investing.com
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Tread Water in Thursday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading - TradingView
European Equities Traded in the US as ADRs Fall in Tuesday Trading - TradingView
Evaxion Biotech stock hits 52-week low at $1.79 amid market challenges - Investing.com
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remain Flat for Week - TradingView
EVAX: Extended Trial is Excellent News - Research Tree
Evaxion Biotech A/SADR to Host Earnings Call - ACCESS Newswire
Evaxion Biotech stock hits 52-week low at $2.22 amid sharp decline - Investing.com
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading - TradingView
Evaxion Biotech A/S ADR (EVAX) Receives Upgrades Amid Sharp Decline – Is It Time for Investors to Reevaluate? - HPBL
Evaxion Biotech (EVAX) Stock Analysis: Price Decline, Analyst Ratings and Financial Ratios – market - HPBL
Evaxion secures Nasdaq listing with equity boost - Investing.com
European Equities Traded in the US as American Depositary Receipts Tread Water in Wednesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading, End Week Up 3.2% - TradingView
Now Is The Time To Build A Position In Evaxion Biotech A/S ADR (NASDAQ:EVAX) - Marketing Sentinel
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading - TradingView
H.C. Wainwright maintains Evaxion stock Buy rating, $14 target - Investing.com
European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading - TradingView
Evaxion Biotech stock hits 52-week low at $2.38 amid market challenges - Investing.com
When Will Evaxion Biotech A/S ADR. (EVAX) Be Worth Investing In? - Marketing Sentinel
Finanzdaten der Evaxion A S Adr-Aktie (EVAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):